JP2009532417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009532417A5 JP2009532417A5 JP2009503536A JP2009503536A JP2009532417A5 JP 2009532417 A5 JP2009532417 A5 JP 2009532417A5 JP 2009503536 A JP2009503536 A JP 2009503536A JP 2009503536 A JP2009503536 A JP 2009503536A JP 2009532417 A5 JP2009532417 A5 JP 2009532417A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkenyl
- alkynyl
- cycloalkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 8
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 206010006451 bronchitis Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 3
- -1 EGFR-inhibitors Substances 0.000 claims 3
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 3
- 230000000172 allergic effect Effects 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 2
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 2
- 206010001889 Alveolitis Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 206010052613 Allergic bronchitis Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 208000027932 Collagen disease Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 208000000592 Nasal Polyps Diseases 0.000 claims 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000003454 betamimetic effect Effects 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229940052760 dopamine agonists Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 244000000013 helminth Species 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000016366 nasal cavity polyp Diseases 0.000 claims 1
- 208000037916 non-allergic rhinitis Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 0 CC(C)(CNC)CN* Chemical compound CC(C)(CNC)CN* 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06112297 | 2006-04-06 | ||
| PCT/EP2007/052916 WO2007115933A1 (de) | 2006-04-06 | 2007-03-27 | Thiazolyl-dihydro-indazole |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009532417A JP2009532417A (ja) | 2009-09-10 |
| JP2009532417A5 true JP2009532417A5 (https=) | 2010-06-03 |
Family
ID=36763499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009503536A Pending JP2009532417A (ja) | 2006-04-06 | 2007-03-27 | チアゾリルジヒドロインダゾール |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20070238718A1 (https=) |
| EP (1) | EP2018387A1 (https=) |
| JP (1) | JP2009532417A (https=) |
| KR (1) | KR20090026129A (https=) |
| CN (1) | CN101466717A (https=) |
| AR (1) | AR060266A1 (https=) |
| AU (1) | AU2007236047A1 (https=) |
| BR (1) | BRPI0709743A2 (https=) |
| CA (1) | CA2647295A1 (https=) |
| IL (1) | IL194496A0 (https=) |
| MX (1) | MX2008012539A (https=) |
| RU (1) | RU2008143557A (https=) |
| TW (1) | TW200806680A (https=) |
| WO (1) | WO2007115933A1 (https=) |
| ZA (1) | ZA200807821B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1994022A2 (en) | 2006-03-15 | 2008-11-26 | Wyeth a Corporation of the State of Delaware | N-substituted-azacyclylamines as histamine-3 antagonists |
| US7691868B2 (en) | 2006-04-06 | 2010-04-06 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-quinazoline |
| US20070238746A1 (en) * | 2006-04-06 | 2007-10-11 | Trixi Brandl | Thiazolyl-dihydro-chinazoline |
| US20070259855A1 (en) * | 2006-04-06 | 2007-11-08 | Udo Maier | Thiazolyl-dihydro-indazole |
| CN101432261A (zh) | 2006-05-19 | 2009-05-13 | 惠氏公司 | 作为组织胺-3拮抗剂的n-苯甲酰基-吡咯烷-3-基胺和n-苄基-吡咯烷-3-基胺 |
| PE20081152A1 (es) | 2006-10-06 | 2008-08-10 | Wyeth Corp | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 |
| CN101778838A (zh) * | 2007-05-24 | 2010-07-14 | 惠氏有限责任公司 | 作为组胺-3拮抗剂的氮杂环基苯甲酰胺衍生物 |
| CA2693138A1 (en) | 2007-07-16 | 2009-01-22 | Wyeth Llc | Aminoalkylazole derivatives as histamine-3 antagonists |
| UY31700A (es) * | 2008-03-13 | 2009-11-10 | Boehringer Ingelheim Int | Tiazolil-dihidro-indazoles |
| US20110230472A1 (en) * | 2008-08-29 | 2011-09-22 | Shionogi & Co., Ltd. | Ring-fused azole derivative having pi3k-inhibiting activity |
| JP5901020B2 (ja) * | 2009-04-22 | 2016-04-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の治療用ＰＩ３−キナーゼ阻害薬としてのチア−トリアザ−ａｓ−インダセン |
| MY160064A (en) * | 2009-09-28 | 2017-02-15 | Hoffmann La Roche | Benzoxazepin pi3k inhibitor compounds and methods of use |
| CN105189485B (zh) | 2013-03-15 | 2017-10-24 | 埃科特莱茵药品有限公司 | 作为抗疟剂的新型丙烯酰胺衍生物 |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2020136650A1 (en) | 2018-12-25 | 2020-07-02 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an egfr inhibitor |
| CA3200111C (en) | 2020-10-28 | 2025-02-18 | Shionogi & Co., Ltd. | AMIDE DERIVATIVE WITH ANTIVIRAL ACTIVITY |
| JP7454729B2 (ja) * | 2022-04-27 | 2024-03-22 | 塩野義製薬株式会社 | 抗ウイルス活性を有するアミド誘導体を含有する医薬組成物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5547975A (en) * | 1994-09-20 | 1996-08-20 | Talley; John J. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
| KR20020084116A (ko) * | 2000-02-07 | 2002-11-04 | 애보트 게엠베하 운트 콤파니 카게 | 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도 |
| DE10344223A1 (de) * | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
| EP2343303A1 (de) * | 2004-10-07 | 2011-07-13 | Boehringer Ingelheim International GmbH | PI3-Kinase Inhibitoren |
| UY29149A1 (es) * | 2004-10-07 | 2006-05-31 | Boehringer Ingelheim Int | Tiazolil-dihidro-indazoles |
-
2007
- 2007-03-23 US US11/690,351 patent/US20070238718A1/en not_active Abandoned
- 2007-03-27 CN CNA200780021166XA patent/CN101466717A/zh active Pending
- 2007-03-27 AU AU2007236047A patent/AU2007236047A1/en not_active Abandoned
- 2007-03-27 JP JP2009503536A patent/JP2009532417A/ja active Pending
- 2007-03-27 RU RU2008143557/04A patent/RU2008143557A/ru not_active Application Discontinuation
- 2007-03-27 EP EP07727389A patent/EP2018387A1/de not_active Withdrawn
- 2007-03-27 MX MX2008012539A patent/MX2008012539A/es not_active Application Discontinuation
- 2007-03-27 KR KR1020087027299A patent/KR20090026129A/ko not_active Withdrawn
- 2007-03-27 WO PCT/EP2007/052916 patent/WO2007115933A1/de not_active Ceased
- 2007-03-27 CA CA002647295A patent/CA2647295A1/en not_active Abandoned
- 2007-03-27 BR BRPI0709743-3A patent/BRPI0709743A2/pt not_active IP Right Cessation
- 2007-04-03 AR ARP070101384A patent/AR060266A1/es unknown
- 2007-04-04 TW TW096111948A patent/TW200806680A/zh unknown
-
2008
- 2008-09-11 ZA ZA200807821A patent/ZA200807821B/xx unknown
- 2008-10-02 IL IL194496A patent/IL194496A0/en unknown
- 2008-11-25 US US12/277,543 patent/US20090093474A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009532417A5 (https=) | ||
| JP2008515852A5 (https=) | ||
| NO20082000L (no) | Pyrimidinamidforbindelser som PGDS-inhibitorer | |
| JP2008520742A5 (https=) | ||
| JP2020510015A5 (https=) | ||
| JP2010540593A5 (https=) | ||
| JP2007502804A5 (https=) | ||
| AR040803A1 (es) | Ligandos de receptores canabinoides, composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos compuestos, solos o combinados, para la preparacion de medicamentos | |
| JP2007515432A5 (https=) | ||
| CA2672373A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| JP2009527501A5 (https=) | ||
| JP2014534222A5 (https=) | ||
| JP2013530179A5 (https=) | ||
| JP2016526023A5 (https=) | ||
| CA2471578A1 (en) | Xanthene-carboxylic acid esters of tropenol and scopine as m3 antagonists, method for producing the same and use thereof as medicaments | |
| JP2015535832A5 (https=) | ||
| JP2021535177A5 (https=) | ||
| JP2007522162A5 (https=) | ||
| RU2008143557A (ru) | Тиазолилдигидроиндазолы | |
| JP2021535174A5 (https=) | ||
| EA200970158A1 (ru) | Производные хинуклидина в качестве антагонистов м3 | |
| JP2008516968A5 (https=) | ||
| JP2007526257A5 (https=) | ||
| JP2013526520A5 (https=) | ||
| JP2009532413A5 (https=) |